Oricell’s GPRC5D-Targeted CAR Cleared for US Evaluation in Patients With R/R Multiple Myeloma

News
Article

Promising data on OriCAR-017 were previously published in the Lancet Haematology in 2023.

 He Huang, MD, PhD

He Huang, MD, PhD

The FDA has cleared Oricell’s investigational new drug (IND) application of OriCAR-017, allowing the company to initiate clinical development for patients with relapsed/refractory multiple myeloma (RR MM) in the United States.1

OriCAR-017 is a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy. The therapy is developed with the use of Oricell's Ori®Ab antibodies and Ori®CAR construct proprietary platforms, designed to achieve optimal binding, superior persistence and anti-tumor efficacy. The FDA IND approval for OriCAR-017 follows its IND approval in China in 2023. 

"The evidenced superior safety, efficacy and durability profile of OriCAR-017 is truly exciting and will significantly benefit multiple myeloma patients on a global scale. Ten years' R&D cumulates not only OriCAR-017 but also the robust and integrated technology platforms that generate one-of-its-kind CAR-T products for liquid and solid tumors," Peter He, cofounder and Chief Scientific Officer, Oricell, said in a statement.1

"Exceptional teamwork is what Oricell relies upon. The fact that we were able to complete technical transfer from China to the U.S. in 5 months speaks for the standard of our teamwork." Helen Yang, cofounder and Chief Executive Officer, Oricell, added.1 "With a great team and support from our stakeholders, we are confident in our ability to delivering best-in-class cell therapies to patients, providing them new hope and possibilities."

READ MORE: Assessing GPRC5D-Targeted CAR T Therapy for R/R Multiple Myeloma

Oricell previously published data on OriCAR-017 in The Lancet Haematology from the phase 1 POLARIS trial (NCT05016778) in 10 patients with RRMM with a median of238 days follow-up (range, 99-345). The investigators found that the therapy had a manageable safety profile, with common Grade 3 or 4 treatment-emergent adverse events including neutropenia, leukopenia, thrombocytopenia and anemia hematologic toxicities, as well as cytokine release syndrome in all participants.2

OriCAR-017 yielded a 100% overall response rate, with 60% stringent complete response (sCR) and 40% very good partial response (VGPR). All patients (100%) achieved MRD negativity (10-5/ml). Of 5 patients that had disease relapse after BCMA CAR T-cell therapy, 2 had sCR and 3 had VGPR. Median progression-free survival had not been reached as of the cutoff date. Two participants experienced disease progression, one with GPRC5D-positive RRMM and the other with GPRC5D-negative RRMM.2

“Advances in the treatment of R/RMM, including the introduction of immunomodulatory drugs, proteasome inhibitors and monoclonal antibodies as well as stem cell transplantation, have prolonged survival in R/RMM patients, the disease remains a clinically incurable plasma cell neoplasm,” He Huang, MD, PhD, professor, Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, said about the data.2 “Nevertheless, almost all R/RMM patients eventually experience one or more relapses, with poorer survival outcomes for those with high-risk cytogenetic characteristics or refractory diseases. Data from our study showed that with extraordinary clinical efficacy, OriCAR-017 has been proved to be a novel, safe and effective therapy for patients with R/RMM, especially for those who experienced a relapse after receiving BCMA-targeted therapy. We are looking forward to continuously conducting follow-up clinical studies of OriCAR-017 in concert with Oricell.”

REFERENCES
1. Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company's Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma. News release. Oricell. January 29, 2024. https://www.prnewswire.com/news-releases/oricell-announces-fda-clearance-of-ind-application-for-oricar-017-a-novel-gprc5d-targeted-car-t-cell-therapy-utilizing-the-companys-proprietary-platform-for-the-treatment-of-relapsedrefractory-multiple-myeloma-302046662.html
2. Oricell Publishes Data from POLARIS Clinical Study Evaluating OriCAR-017 in the Treatment of RRMM in. January 31, 2023. https://www.oricell.com/en/newsdetail/id/15.html
Related Videos
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
John DiPersio, MD, PhD, the director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine
Aude Chapuis, MD, an associate professor in the Translational Science and Therapeutics Division at Fred Hutch Cancer Center
© 2024 MJH Life Sciences

All rights reserved.